Day 1, Thursday, May 23rd
08:30-10:00 BCMA-targeted therapies in myeloma: the new treatment frontier
Pre-COMy IME Symposium
10:00-10:20 Coffee Break
10:20-10:30 COMy 2024 kick-off
10:30-12:00 Session 1:
Defining risk in myeloma
12:00-12:30 Lunch Break
12:30-14:00 To BCMA or not to BCMA? Addressing unanswered questions in RRMM
Industry-supported Lunch Symposium
by Johnson & Johnson
14:00-14:10 Technical Break
14:10-15:35 Session 2:
Novel approaches for disease and response assessment
15:35-15:45 Technical Break
15:45-17:15 Is MRD ready for prime time for multiple myeloma patients?
Industry-supported Symposium
by Adaptive Biotechnologies
17:15-17:30 Coffee Break
17:30-18:30 Session 3:
Precursor conditions and other plasma cell disorders
18:30-19:15 Session 4:
Plenary lectures
Day 2, Friday, May 24th
08:15-08:30 Good Morning Breakfast
08:30-09:20 Session 5:
IMS Session
09:20-09:30 Technical Break
09:30-11:00 Harnessing the Immune System: New Emerging Data in Multiple Myeloma
Industry-supported Symposium
by BMS
11:00-11:20 Coffee Break
11:20-12:30 Session 6:
Frontline management of newly diagnosed myeloma
12:30-13:00 Lunch Break
13:00-14:30 More choices, more flexibility: Individualising and optimising treatment in NDMM
Industry-supported Lunch Symposium
by Johnson & Johnson
14:30-14:45 Technical Break
14:45-15:45 Session 7:
Practical management of specific situations
15:45-16:00 Coffee Break
16:00-17:30 Going for Gold: Making Strides in Multiple Myeloma Treatment Strategies
Industry-supported Symposium
by Sanofi
17:30-17:45 Technical Break
17:45-18:45 Session 8:
Plenary lectures
18:45-19:15 COMy Award Ceremony
Day 3, Saturday, May 25th
08:00-08:10 Good Morning Breakfast
08:10-09:10 Session 9:
Novel agents under development
09:10-09:20 Technical Break
09:20-10:50 Is there a place for BCMA-based combinations in early RRMM?
Industry-supported Symposium
by GSK
10:50-11:10 Coffee Break
11:10-12:30 Session 10:
How I treat a relapsed/refractory myeloma
12:30-13:00 Lunch Break
13:00-14:00 An innovative therapeutic option in the treatment of triple-class exposed relapsed refractory multiple myeloma (TCE RRMM)
Industry-supported Lunch Symposium
by Pfizer
14:00-14:10 Technical Break
14:10-14:55 Management of triple-class refractory patients in the absence of immunotherapies
14:55-16:10 Session 11:
The road to cure: future protocols and directions
16:10-16:30 Coffee Break
16:30-17:30 Expanding Frontline Frontiers in MM: Insights on Delivering Modern Care With Innovative CD38 Quadruplet Platforms
CME Symposium
17:30-17:40 Technical Break
17:40-18:10 Session 12:
Plenary lecture
18:10-18:20 In-Person Conclusions
Day 4 (ONLINE ONLY), Sunday, May 26th
10:00-11:15 Multiple Myeloma communications I
11:15-11:30 Short Break
11:30-12:30 Transforming Progress into Action in Relapsed/Refractory Multiple Myeloma: Improving Patient Outcomes Through Innovative Bispecific Antibodies
Virtual CE Symposium
12:30-13:45 Mulitple Myeloma communications II
13:45-14:15 Final Panel Discussion and Conclusion